Full Press Release Details
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology has initiated ALISCA®-Lung2, a Phase II trial of alisertib in combination with paclitaxel to treat advanced small cell lung cancer.
PBYI Positive Sentiment
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
Key Takeaway: Puma Biotechnology has launched the ALISCA®-Lung2 trial, a Phase II study evaluating the efficacy of alisertib combined with paclitaxel for patients suffering from advanced small cell lung cancer. This initiative represents a significant step forward in addressing treatment options for this challenging cancer type.
Market Sentiment Analysis
POSITIVE FACTORS
- Initiation of a Phase II trial indicates progress in cancer treatment.
- Combination therapy may enhance treatment efficacy for patients.
- Focus on advanced small cell lung cancer addresses a significant medical need.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+56%
120-day peak, hindsight
Typical move
1.7%
average across 3 past catalysts
Lead asset
Alisertib
Phase 1 · Lung Cancer Metastatic
Frequently Asked Questions
What is the ALISCA®-Lung2 trial?
The ALISCA®-Lung2 trial is a Phase II study initiated by Puma Biotechnology.
What treatments are being tested in the trial?
The trial tests alisertib in combination with paclitaxel.
What type of cancer is the trial focused on?
The trial focuses on advanced small cell lung cancer.
Who initiated the ALISCA®-Lung2 trial?
Puma Biotechnology has initiated the ALISCA®-Lung2 trial.